上海2026年8月5日 /美通社/ -- 雲頂新耀（HKEX 1952.HK），一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈公司將於北京時間2026年8月19日公佈2026年度中期業績及業務進展，並於當日舉行線上投資人會議。

會議時間：北京時間2026年8月19日，星期三，上午8:30（美國東部時間8月18日晚間8:30）

參會者可通過以下鏈接參與中文會議及英文同聲傳譯：

中文會議：

網絡參會：https://research.citics.com/tel/info/1_2232800

電話參會：

中國大陸 4008108228/4008108128
海外         861058084166
中國香港 85230051313/85230051355
中國台灣 0800666425
新加坡     6568185374
美國         16462543594
英國         441213680466
電話參會密碼：834993

同聲傳譯（英文）鏈接：

網絡參會：https://clsa.zoom.com/webinar/register/WN_CZKptYYzT5a-NKhgC7t7vw

有關雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、美國及歐盟標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明：

本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2026, and provide a business update on Aug. 19, 2026. The Company will hold an online investor call on the same day.

Time: 8:30 AM Beijing Time, Wednesday, August 19, 2026 (8:30 PM U.S. Eastern Time, August 18, 2026)

For Chinese Session:

Webcast Link: https://research.citics.com/tel/info/1_2232800

Alternatively, participants may dial in to the conference call using the below dial-in information:

Chinese Mainland:     4008108228/4008108128
Overseas:                   861058084166
Hong Kong, China:    85230051313/85230051355
Taiwan, China:           0800666425
Singapore:                  6568185374
U.S.:                           16462543594
UK:                            441213680466
Password：                834993

The webcast also provides simultaneous interpretation in English:

Webcast Link: https://clsa.zoom.com/webinar/register/WN_CZKptYYzT5a-NKhgC7t7vw

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. 

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Apple Inc. (AAPL.US) attempted to introduce CXMT (688825.SH) as its third DRAM supplier to lower future iPhone costs, foreign reports said.

However, CXMT refused to make price concessions, with its quotations similar to or even higher than those offered by Apple's existing suppliers Samsung Electronics and SK Hynix.

Huawei, XIAOMI-W (01810.HK) and other Chinese OEM have already signed long-term supply agreements with CXMT at high prices, leaving CXMT with little incentive to compete for Apple's orders with discounted pricing, sources said.
~

AASTOCKS Financial News
Website: www.aastocks.com

Space Exploration Technologies Corp. (SPCX.US) shares plunged during pre-market trading on Wednesday (5th) after a spike in the company's AI spending raised investor concerns, overshadowing better-than-expected quarterly results. The stock last tumbled 10.4% in pre-market trading.

On Tuesday (4th), SpaceX released its first earnings report as a listed company. The space enterprise owned by CEO Elon Musk said capital expenditure in 2Q26 mushroomed sixfold to USD18.4 billion, exceeding analyst expectations, with most of the spending directed toward AI.

The company's shares closed slightly above USD125 on Tuesday, still below its IPO price of USD135 and markedly lower than the record high of more than USD200 reached shortly after listing.

During the current earnings season, market concerns have intensified over whether major technology companies can demonstrate returns from multi-billion-USD investments, weighing on investor sentiment.

Although the market believes SpaceX's proprietary models lag behind OpenAI and Anthropic, the company is positioning itself as an alternative cloud service provider by leasing computing capacity built with NVIDIA Corporation (NVDA.US) chips.

In addition, the company will face another potentially market-moving event on Thursday (6th), when the insider share lock-up period expires, allowing insiders to sell part of their holdings.
~

AASTOCKS Financial News
Website: www.aastocks.com

First integrated tourism and leisure enterprise in Greater China
to receive this recognition

MACAO, Aug. 5, 2026 /PRNewswire/ -- In recognition of its people-centric corporate culture and outstanding workplace environment, Sands China Ltd. has been awarded the Great Place To Work Certification™ upon its first participation in the assessment conducted by Great Place To Work™, a global authority on workplace culture. The company has become the first integrated tourism and leisure enterprise in Greater China to achieve this honour.

Headquartered in the United States, Great Place To Work™ serves over 22,000 organizations worldwide. Its Great Place To Work Certification™ is primarily evaluated based on anonymous Trust Index™ Survey data submitted by employees of participating organizations, combined with a comprehensive review of the company's workplace culture and management practices. The survey assesses employees' level of trust and workplace experience across five key dimensions: Credibility, Respect, Fairness, Pride, and Camaraderie.

In the assessment survey conducted among Sands China team members, an impressive 96 percent of surveyed team members agreed that Sands China is a great place to work, with the company achieving an average score of 92 percent in the five evaluation categories. The survey results fully demonstrate the effectiveness of the company's long-term investment in promoting career development, safeguarding team members' physical and mental well-being, fostering a fair, caring, and supportive workplace culture, and building a high-trust management team.

Grant Chum, chief executive officer and executive director of Sands China Ltd., said: "We are honoured that Sands China has become the first integrated tourism and leisure enterprise in the Greater China region to earn the Great Place To Work Certification™. The significance of this accolade extends beyond recognition from an authoritative international organization. It also reflects the immense trust that our 28,000 team members have placed in the company and their strong belief in the people-centric corporate culture we have cultivated together over the years. It is this deep trust and cohesion that inspires our team to maintain a unified focus – continuously elevating our operational excellence, enhancing service quality, and setting new industry standards. This recognition reinforces our strong confidence in Sands China's long-term development and our belief that through our collective efforts, the company will continue to advance and scale new heights.

"I extend my heartfelt gratitude to every team member for their unwavering dedication and outstanding contributions. Moving forward, Sands China remains committed to supporting the Macao SAR government's talent development strategies. We will continue to expand career advancement opportunities for local talent while collaborating across sectors to foster Macao's economic diversification and reinforce its positioning as a World Centre of Tourism and Leisure."

Since 2025, Sands China has also been recognized for two consecutive years as a "Top Employer" by the Top Employers Institute, one of the world's most authoritative certifiers of human resources strategies, acknowledging the company's outstanding performance in talent policy and practice. Earning the Great Place To Work Certification™ further validates the effectiveness of the company's HR strategy through employees' feedback on their experiences. These two respected certifications complement each other, highlighting Sands China's consistent achievements in talent development, employee well-being, and corporate culture.

As Macao's largest private employer, Sands China continuously aligns with the Macao SAR government's policy strategy of "Building Macao through Talent Training." Focusing on three core pillars of attracting, developing, and retaining talent, the company regularly launches people-centric HR initiatives to build a healthy, supportive, efficient, and inclusive work environment.

Through its eight specialized sub-academies under the Sands China Academy, the company offers professional training in diverse fields – MICE, hospitality, integrated resort management, entertainment, facilities, responsible gaming, procurement, and retail – providing team members with vertical and horizontal career advancement opportunities. The cumulative training delivered to team members has surpassed 22.6 million hours, as of the end of 2025.

In terms of employee well-being and workplace inclusion, the company has introduced several family-friendly measures, such as providing seven days of paid paternity leave, up to six days of paid Child Care Leave and a 90-consecutive-day Parenthood Support Shift, actively fostering a family-friendly workplace. Additionally, the company has introduced AI-powered health monitoring tools to help employees identify health risks early. At the same time, Sands China actively promotes a culture of diversity and inclusion. Its initiative to create new positions specifically for people with disabilities was recognised in the Top Employers Institute's white paper as a best practice.

By the end of 2026, nearly 15,000 team members will have reached a tenure of 10 or more years, accounting for over half of the company's current workforce. This underscores team members' strong sense of belonging and enduring connection towards the company's corporate culture.

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Media contacts:

Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

CHONGQING, China, Aug. 5, 2026 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") has commissioned a specialty polyvinyl alcohol (PVA) resin facility with an annual production capacity of 50,000 metric tons at its subsidiary, Chongqing SVW Chemical Co., Ltd. The facility achieved stable operation during its initial startup and produced products that met quality specifications, with the first shipment already sent to Europe.

The new facility increases the site's total PVA production capacity to 210,000 metric tons per year, making it the world's largest single-site production base for high-end PVA. The additional capacity will strengthen the supply of specialty materials used in photovoltaics, electronics, optical films, pharmaceuticals and other high-value applications.

PVA is a water-soluble polymer with biodegradable properties and a broad range of industrial and consumer uses. Specialty grades with high purity and transparency are used in optical films, polarizers, pharmaceutical products and safety glass for automobiles and high-speed trains. PVA is also used in textiles, construction materials and water-soluble packaging.

SVW Chemical offers more than 100 PVA grades designed for different performance requirements and market applications. The new facility uses advanced alcoholysis and precision purification technologies to support the large-scale production of specialty PVA products.

During construction, the project team addressed technical challenges involving precise temperature control and consistent product quality. A new polymerization process increased production capacity by 40% compared with earlier-generation equipment. The facility also incorporates four exhaust gas and wastewater recovery units, along with an automated packaging system, to improve resource efficiency and operational efficiency.

The project was completed in 17 months and recorded 1.98 million safe working hours. During commissioning, the team optimized equipment performance and process parameters to achieve stable production and consistent product quality.

SVW Chemical has more than 40 years of experience in PVA research and manufacturing. Its portfolio has grown from one PVA grade at the beginning of operations to more than 100 today. More than 70 products are exported to over 40 countries, providing the company with an established foundation in international markets, including Europe and the United States.

Moving forward, SVW Chemical will use its expanded capacity and research capabilities to develop additional high-value specialty materials, broaden its PVA portfolio and provide customers worldwide with a more reliable supply.

成為大中華區首家獲認證的綜合旅遊休閒企業

澳门2026年8月5日 /美通社/ -- 金沙中國有限公司憑藉以人為本的企業文化及卓越職場環境，首次參與全球職場文化權威機構Great Place To Work™ 評選，即通過國際標準獲頒Great Place To Work 認證™，成為大中華區首家獲此認證的綜合旅遊休閒企業。

Great Place To Work™ 總部位於美國，服務全球超過22,000家企業。而其Great Place To Work 認證™主要基於參與機構的員工以匿名填報的 Trust Index^©員工調研數據作評估，並結合對企業職場文化及管理實踐的綜合審視。調研分別從信賴、尊重、公平、自豪及友愛五大範疇，評估員工對機構的信任程度及職場體驗。

今年，在金沙中國團隊成員參與的評估調研中，高達96%的受訪團隊成員認同金沙中國為理想工作場所，而公司在各評估範疇的平均得分達92%。調研結果充分體現團隊成員肯定公司在推動員工職涯發展、保障身心健康，以及營造公平、關愛、互助的職場文化與建立互信管理團隊等方面的長期投入與成效。

金沙中國有限公司行政總裁兼執行董事鄭君諾表示：「我們十分榮幸金沙中國成為大中華區首家榮獲Great Place To Work 認證™的綜合旅遊休閒企業。這項國際認證的意義不僅在於獲得國際權威機構的肯定，更印證了全體28,000名團隊成員對公司的信任，以及對我們多年來攜手建立、以人為本企業文化的高度認同。正是這份深厚的信任與凝聚力，推動團隊上下一心，不斷提升服務和營運水平，共同樹立行業標竿。這項認證亦進一步增強了我們對金沙中國長遠發展的信心，讓我們堅信，在全體團隊成員的共同努力下，公司未來將持續成長，再創佳績。我衷心感謝每一位團隊成員一直以來的卓越貢獻。未來，金沙中國將繼續積極配合澳門特區政府的人才發展方針，持續為本澳人才創造更多晉升與發展機會，攜手各界推動澳門經濟多元發展，助力鞏固澳門『世界旅遊休閒中心』的定位。」

2025年起，金沙中國連續兩年獲全球人力資源戰略的認證權威「傑出僱主調研機構」頒發「傑出僱主」認證，肯定公司在人才政策與實踐上的卓越表現；是次榮獲Great Place To Work 認證™，則進一步從員工的真實體驗，印證公司人力資源策略的實效。兩項權威認證相得益彰，充分彰顯金沙中國在人才培育、員工福祉及企業文化的卓越成果。

作為澳門最大私營僱主，金沙中國一直全力配合澳門特區政府「人才建澳」施政方針，並聚焦「引才、育才、留才」三大核心，持續推出各項以人為本的人力資源措施，致力打造健康友善、高效共融的職場環境。公司透過旗下「金沙中國學院」的八大專業學院，提供涵蓋會展、酒店管理、綜合度假村管理、娛樂表演、設施管理、負責任博彩、採購和零售等不同範疇的專業培訓，為團隊成員提供向上及橫向流動的職業發展機會。截至2025年底，公司為團隊成員提供的累計培訓總時數已超過2,260萬小時。

在員工福祉及職場共融方面，公司先後推出多項家庭友善措施，如提供7日有薪侍產假、最多6日的有薪「育兒陪護假」及連續90日的「育兒支援更」，積極構建家庭友善職場，並引入結合人工智能的健康檢測工具，協助員工及早辨識健康風險。同時，公司積極推動多元包容文化，特別為殘疾人士開設新職位的舉措，更被「傑出僱主調研機構」白皮書列為最佳實踐案例。在2026年，累計服務滿10年或以上的團隊成員一共有近15,000人，佔公司員工總數逾半，充分展現團隊對公司企業文化的高度歸屬感與認同。

關於金沙中國有限公司

金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

傳媒查詢：

金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected] 

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

Michael Burry, the renowned US hedge fund manager portrayed in "The Big Short", maintained his bearish stance even as the S&P 500 hit a record high. He warned that the current rally could ultimately end in a collapse similar to the 1987 stock market crash.

Although new highs in the S&P 500 may attract fresh capital into the market, he still believed US stocks are approaching a major peak and could experience a plunge similar to that seen in 1987.

Supported by corporate earnings beat and growing hopes that the Strait of Hormuz will reopen, US stocks stretched upswing for a fourth consecutive trading day overnight (4th), with the three major indices mounting nearly 2% or more. Both the DJIA and the S&P 500 notched fresh intraday and closing highs.

Burry believed demand for AI infrastructure may be driven by unsustainable financing arrangements. He said the market rally is creating a self-reinforcing cycle, while lower volatility is encouraging systematic investors to increase risk exposure.

He emphasized that he will continue to hold short positions in iShares PHLX SOX Semiconductor Sector Index Fund (SOXX.US), Micron Technology, Inc. (MU.US), NVIDIA Corporation (NVDA.US), Caterpillar, Inc. (CAT.US), Palantir Technologies Inc. (PLTR.US), Tesla, Inc. (TSLA.US) and Applied Materials, Inc. (AMAT.US), and remains highly confident about the long-term outlook for these positions.

However, he would cut losses promptly if the trades move significantly against him. Apart from the short position in NVIDIA, all other positions currently remain profitable.
~

AASTOCKS Financial News
Website: www.aastocks.com

After capex for AI business of Space Exploration Technologies Corp. (SPCX.US) sharply topped expectations, company executives on Tuesday (4th) sought to assure investors that the investment is valuable and said the company could recoup costs within one year.

SpaceX released its first earnings report since its June listing, with shares falling after the results. 2Q26 revenue leaped 92% YoY, beating market expectations, but capex jumped up more than sixfold to USD18.4 billion, more than double quarterly total sales.

More than 80% of SpaceX's capex was directed toward AI. The company trails OpenAI, Anthropic and Google in models and services, and is competing in the cloud market with Microsoft Corporation (MSFT.US), Amazon.com, Inc. (AMZN.US) and Google by selling computing capacity.

According to market data, the USD18.4 billion capex topped analysts' average estimate of USD13.22 billion. SpaceX shares fell off 7.5% in after-hours trading, almost erasing earlier gains and trading more than 20% below the first-day trading price on June 12.
~

AASTOCKS Financial News
Website: www.aastocks.com

Space Exploration Technologies Corp. (SPCX.US)'s 2Q revenue spiked 92% YoY to USD7.8 billion, topping analysts' expectations, while loss narrowed to USD541 million from USD1.008 billion in the same period last year.

The AI division posted an operating loss of USD1.26 billion, while the space division recorded a loss of USD542 million. The network connectivity business continued to post a profit, with operating profit reaching USD1.66 billion.

Following the earnings release, the company's share price fell 7.46% in after-hours trading.

SpaceX CEO Elon Musk said the company will fully build future AI services based on NVIDIA Corporation (NVDA.US) systems, as he believes the Vera Rubin multi-rack POD-level system is the best and highly values the partnership with NVIDIA.

Musk said in May that Tesla, Inc. (TSLA.US) and SpaceX would likely continue purchasing chips from both NVIDIA and Advanced Micro Devices, Inc. (AMD.US).

However, after Musk's latest remarks that SpaceX would fully adopt NVIDIA systems, NVIDIA shares jumped up 2.16% in after-hours trading, while AMD dived nearly 9%.
~

AASTOCKS Financial News
Website: www.aastocks.com